The IMF is Proud to Announce the New and Improved Myeloma Matrix 2.0: Clinical Trial Search. This comprehensive and easy-to-use clinical trial resource has been vastly improved. Myeloma Matrix 2.0: Smart Search is an important tool for the entire myeloma community, and is easy to navigate. The new Myeloma Matrix helps patients gain knowledge about myeloma drugs currently under development and tracks them through all phases from Pre-Clinical (laboratory-only) to FDA approval.Search this tool here
Understanding that the search for a cure for multiple myeloma demands constant innovation, the IMF has launched the Black Swan Research Initiative (BSRI®), a unique project to develop the first definitive cure for myeloma.Through medical innovation we can already achieve long-term complete remissions in 15 to 20 percent of myeloma patients. Now, by identifying the best treatments at the best time to achieve the best objective, we’re ready to bridge the gap from long-term remission to cure. Click Here to Learn More About BSRI
The mission of the IMWG is to conduct basic, clinical and translational research in a collaborative manner to improve outcomes in myeloma, and to provide scientifically valid and critically appraised consensus opinions on the diagnosis and treatment of myeloma and related disorders. In further pursuit of this mission, IMWG holds an annual summit to identify, support, and implement the most promising research to prevent onset of active disease, improve treatment, and find a cure for myeloma.Click here to learn more about the IMWG
The IMF produces and maintains an extensive library of up-to-date educational publications for patients and caregivers, as well as for healthcare professionals.Please click to read IMF materials.